Coronary Artery Disease, Coronary Disease, Heart Diseases, Myocardial Ischemia
Conditions
Keywords
Promus PREMIER, Routine Clinical Practice
Brief summary
The purpose of this study is to evaluate effectiveness and safety of Promus PREMIER in Routine Clinical Practice
Interventions
DEVICEPromus PREMIER
Sponsors
CardioVascular Research Foundation, Korea
Boston Scientific Korea Co. Ltd
Seung-Jung Park
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 20 and more * Intervention with Promus PREMIER everolimus eluting coronary stent * Agreed with written informed consent form
Exclusion criteria
* Intervention with Promus PREMIER everolimus eluting coronary stent and other drug eluting stent at the same time * Life expectancy of 1year and under * Cardiac shock
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite event rate | 1year | Death, non fatal myocardial infarction, Target Vessel Revascularization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Composite event of cardiac death or myocardial infarction | 5year | — |
| Target Vessel revascularization | 5year | — |
| Target lesion revascularization | 5year | — |
| Stent thrombosis by an Academic Research Consortium (ARC) criteria | 5year | — |
| Composite event of death or myocardial infarction | 5year | — |
| All death | 5year | — |
| Cardiac death | 5year | — |
| Myocardial infarction | 5year | — |
| Procedural success | 3day | defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days. |
| Stroke | 5year | — |
Countries
South Korea
Outcome results
None listed